All articles tagged with #amylin
Eli Lilly's experimental obesity drug, eloralintide, shows promising results in mid-stage trials, with significant weight loss and improved health markers, leading to plans for late-stage trials and potential as an alternative to existing therapies.
Scientists have discovered new insights into the hormone amylin, which could lead to more effective weight-loss medications by better understanding its receptors, potentially speeding up the development of next-generation obesity drugs like amylin-based treatments currently in trials.
Novo Nordisk's new amylin-based obesity drug, amycretin, shows significant weight loss in early trials, but similar efficacy across different doses and high side effects raise questions about optimal dosing strategies.
Metsera's experimental drug targeting the amylin hormone showed promising results in early clinical trials, indicating potential for longer-lasting weight loss effects compared to existing weekly injections, highlighting a significant development in obesity treatment.
Metsera's experimental obesity drug targeting amylin shows promising early results, with significant weight loss observed in initial trials, suggesting it may offer longer-lasting effects than current weekly injections.